Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH) announced that the company has recently received the Drug Registration Certificate for Carbasalate Calcium Injection approved and issued by the National Medical Products Administration. Carbasalate Calcium Injection is indicated for bleeding disorders in the urinary system, upper gastrointestinal tract, respiratory tract, and gynecological and obstetric conditions, with particularly significant therapeutic effects on urinary system disorders. The medication can also be used for the prevention and treatment of surgical bleeding.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments